220 related articles for article (PubMed ID: 19217287)
1. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Bamaung NY; Palazzo F; Zhang Q; Kovar P; Osterling DJ; Hu X; Wilsbacher JL; Johnson EF; Bouska J; Wang J; Bell RL; Davidsen SK; Sheppard GS
Bioorg Med Chem Lett; 2007 Oct; 17(19):5406-9. PubMed ID: 17689078
[TBL] [Abstract][Full Text] [Related]
3. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
Fidanze SD; Erickson SA; Wang GT; Mantei R; Clark RF; Sorensen BK; Bamaung NY; Kovar P; Johnson EF; Swinger KK; Stewart KD; Zhang Q; Tucker LA; Pappano WN; Wilsbacher JL; Wang J; Sheppard GS; Bell RL; Davidsen SK; Hubbard RD
Bioorg Med Chem Lett; 2010 Apr; 20(8):2452-5. PubMed ID: 20346655
[TBL] [Abstract][Full Text] [Related]
4. Advances towards the development of ATP-competitive small-molecule inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Wilsbacher JL
ChemMedChem; 2007 Jan; 2(1):41-6. PubMed ID: 17089440
[No Abstract] [Full Text] [Related]
5. Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family.
Teller N; Thiele W; Boettler U; Sleeman J; Marko D
Mol Nutr Food Res; 2009 Sep; 53(9):1075-83. PubMed ID: 19653223
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy--clinical progress.
Renhowe PA
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):214-24. PubMed ID: 11926128
[TBL] [Abstract][Full Text] [Related]
7. Signal transduction. Autoinhibition control.
Schlessinger J
Science; 2003 May; 300(5620):750-2. PubMed ID: 12730587
[No Abstract] [Full Text] [Related]
8. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Tao Y; Pinzi V; Bourhis J; Deutsch E
Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase inhibitors.
Haluska P; Adjei AA
Curr Opin Investig Drugs; 2001 Feb; 2(2):280-6. PubMed ID: 11816845
[TBL] [Abstract][Full Text] [Related]
11. Structural relationships between the insulin receptor and epidermal growth factor receptor families and other proteins.
Ward CW; Garrett TP
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):630-8. PubMed ID: 15503865
[TBL] [Abstract][Full Text] [Related]
12. Growth factor receptors: implications in tumor biology.
Srinivasan DM; Kapoor M; Kojima F; Crofford LJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1246-9. PubMed ID: 16370390
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiproliferative properties of 4-aminoquinazoline derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
Bouey-Bencteux E; Loison C; Pommery N; Houssin R; Hénichart JP
Anticancer Drug Des; 1998 Dec; 13(8):893-922. PubMed ID: 10335266
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinases regulate alpha1D-adrenoceptor signaling properties: phosphorylation and desensitization.
Rodríguez-Pérez CE; Calvo-Ochoa E; Kalashnikova EV; Reyes-Cruz G; Romero-Avila MT; García-Sáinz JA
Int J Biochem Cell Biol; 2009 Jun; 41(6):1276-83. PubMed ID: 19038360
[TBL] [Abstract][Full Text] [Related]
16. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.
Fry DW
Anticancer Drug Des; 2000 Feb; 15(1):3-16. PubMed ID: 10888032
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
19. Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.
Wang GT; Mantei RA; Hubbard RD; Wilsbacher JL; Zhang Q; Tucker L; Hu X; Kovar P; Johnson EF; Osterling DJ; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
Bioorg Med Chem Lett; 2010 Oct; 20(20):6067-71. PubMed ID: 20817523
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
